2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Published: November 20, 2020
- Shared decision making (SDM), a dialogue between patients and their care team, that includes full disclosure of all testing and/or treatment options, discussion of the risks and benefits of those options, and, importantly, engagement of the patient to express their own goals is particularly relevant in the management of conditions such as hypertrophic cardiomyopathy (HCM).
- Counseling patients with HCM regarding the potential for genetic transmission of HCM is one of the cornerstones of care.
- Increasingly, data affirm that the beneficial effects of exercise on general health can be extended to patients with HCM.
Supporting Materials
- Top Things to Know: 2020 AHA/ACC Hypertrophic Cardiomyopathy Guideline
- Executive Summary
- Guidelines Slide set (PDF)
- Clinical Update: Clinical Implications of Genetic Testing in Hypertrophic Cardiomyopathy Slide Set (PDF)
- Clinical Update: Clinical Implications of Genetic Testing in Hypertrophic Cardiomyopathy Customizable Slide Set (PPTX)
- News Release: Hypertrophic Cardiomyopathy Guideline Encourages Shared Decision-Making